SHAREABLE PDF

Current challenges in the management of nonsmall cell lung cancer brain metastases

Lizza E.L. Hendriks[1], Jacques Cadranel[2] and Thierry Berghmans[3]

Affiliations: [1]Dept of Pulmonary Diseases, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, The Netherlands. [2]Service de Pneumologie, Assistance Publique Hôpitaux de Paris, Hôpital Tenon and Sorbonne Université, Paris, France. [3]Dept of Intensive Care and Oncologic Emergencies & Thoracic Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

Correspondence: Lizza E.L. Hendriks, Dept of Pulmonary Diseases, Maastricht University Medical Center+, PO Box 5800, 6202 AZ Maastricht, The Netherlands. E-mail: lizza.hendriks@mumc.nl

@ERSpublications
Brain metastases remain a major problem in NSCLC. Major improvements in systemic therapies have been observed during the past decade but their impact on brain metastases control as well as their combination with radiation techniques needs further research. http://bit.ly/2Jn4v5a

Cite this article as: Hendriks LEL, Cadranel J, Berghmans T. Current challenges in the management of nonsmall cell lung cancer brain metastases. *Eur Respir J* 2020; 55: 1901686 [https://doi.org/10.1183/13993003.01686-2019].

In May 2019, the third European Respiratory Society research seminar of the Thoracic Oncology Assembly entitled "New biomarkers, molecules and therapeutic sequences for non-small cell lung carcinoma (NSCLC) in the era of precision medicine" was held in Paris, France. The previous two seminars of the Thoracic Oncology Assembly were on targeted therapy (2015) [1] and immune checkpoint inhibitors (ICI, 2017) [2]. During this seminar, breakout sessions on difficult situations were organised. One of the most original and useful was on the current challenges in brain metastases (BM) management, that we propose to share with *European Respiratory Journal* readers.